Summary of Key Points from the Conference Call Company and Industry Involved - The conference call discusses **Johnson & Johnson** and its developments in the **prostate cancer treatment** sector, specifically focusing on the **mCRPC (metastatic castration-resistant prostate cancer)** treatment landscape. Core Insights and Arguments - **Patient Baseline**: A total of **51 patients** were enrolled, with a median of **3 lines of mCRPC treatment**. Among these, **43.1%** had previously been treated with **docetaxel**, and **19.6%** had received treatment with **Pluvicto** [1]. - **Efficacy Results**: - In the overall population, the **PSA50** response rate was **64.7%**, and the **PSA90** response rate was **35.3%**. - For patients who had not been treated with taxanes, the **PSA50** response rate was **75.0%**, and the **PSA90** response rate was **46.4%** [1]. - **Safety Profile**: The incidence of grade ≥3 treatment-related adverse events (TRAE) was reported at **27.5%**, with **2.0%** specifically related to pasritamig. No cases of any grade of **cytokine release syndrome (CRS)** were observed, indicating a significant safety advantage [1]. Other Important but Potentially Overlooked Content - **Domestic Prostate Cancer TCE Landscape**: - **Fuhong Hanlin's HLX3902** (CD3/STEAP1/CD28) is currently in the preclinical stage. - **Anmai Biotech's EM1031** (CD3/KLK2) has been licensed to **Juri Biosciences** [1].